Advertisement
neetu chandra sharma
Neetu Chandra Sharma

Neetu Chandra Sharma

tvtn

neetu.chandra@aajtak.com

Neetu Chandra Sharma is a Senior Editor at Business Today, where she leads the magazine’s coverage of healthcare and pharmaceuticals. With over two decades of experience in top Indian newsrooms—including Mint, Hindustan Times, the India Today Group, and Zee Media—she has consistently reported on the intersection of public health policy, corporate healthcare, and the pharmaceutical industry. Her journalism spans policy deep dives, industry trends, regulatory shifts, and corporate strategy across India’s thriving hea...

SHOW MORE...

For the December quarter, Max Healthcare's network gross revenue rose 10% year-on-year to ₹2,608 crore.

Max Healthcare discontinues patented cancer drugs, writes to CGHS to review pricing

by Neetu Chandra Sharma |Feb 6, 2026

Max Healthcare Institute Ltd announced its financial and operating results for the third quarter and nine months ended December 31, 2025, on Thursday.

Will cancer drugs become cheaper in India after Budget 2026's duty cuts?

Will Union Budget 2026’s cancer drug duty cuts actually lower treatment costs?

by Neetu Chandra Sharma |Feb 6, 2026

Study notes lowering taxes on finished cancer drug formulations does not automatically lead to price reductions for patients.

India amended its New Drugs and Clinical Trials Rules in 2023 to permit the use of non-animal, human-relevant testing approaches such as organoids, organ-on-chip systems and computational models.

Why animal testing still drives drug approvals in India, and what it costs pharma?

by Neetu Chandra Sharma |Feb 5, 2026

The report compares India’s non-clinical drug approval framework with regulatory practices in the US, European Union, the UK and Japan. It highlights areas where Indian regulators continue to require ...

Metropolis Q3FY26 Growth Led By Specialty, Wellness Diagnostics

Metropolis Q3FY26 Growth Led By Specialty, Wellness Diagnostics

by Neetu Chandra Sharma |Feb 5, 2026

Metropolis Healthcare Ltd reported Q3FY26 results with profit rising 63% year-on-year and revenue increasing 26% to ₹406 crore, supported by higher patient and test volumes and a higher contribution f...

Global net sales stood at DKK 309,064 million (approximately ₹37.1 lakh crore) in 2025, while operating profit declined 0.5% to DKK 127,658 million (around ₹15.3 lakh crore)

Novo Nordisk’s global growth cools to 6.4%, but India and APAC defy slump

by Neetu Chandra Sharma |Feb 5, 2026

In a year when global operating profit dipped 0.5% due to restructuring costs, APAC sales rose 19%, or 25% at constant exchange rates, far outpacing the company’s global growth rate

While the tariff cut applies to Indian exports to the US, industry executives say stronger overseas demand can have limited spillover effects at home.

US tariff cut to 18%: what it means for pharma and medical devices

by Neetu Chandra Sharma |Feb 3, 2026

India’s manufacturing exports to the US span pharmaceuticals, medical devices, speciality chemicals and intermediates, segments where tariff stability is a key factor in contracting and capacity plann...

Institutional assessments have also pointed to policy support for biologics and healthcare services.

Budget 2026 puts API makers, specialty pharma, and diagnostics in pole position

by Neetu Chandra Sharma |Feb 2, 2026

Union Budget 2026: Biologics and biosimilars were also highlighted as segments drawing sustained investor interest.

Union Budget 2026: A substantial share of the additional funding has gone towards health infrastructure.

Union Budget 2026 lifts health allocation by nearly 10%

by Neetu Chandra Sharma |Feb 1, 2026

Union Budget 2026: Finance Minister Nirmala Sitharaman indicated the government would continue to increase spending on healthcare infrastructure, research and regulation, particularly as disease patte...

To address concerns around quality and standardisation, the Finance Minister announced upgrades to regulatory infrastructure.

Union Budget 2026 steps up push for Ayurveda, AYUSH certification, exports

by Neetu Chandra Sharma |Feb 1, 2026

Union Budget 2026: Key element of plan is creation of five Regional Medical Hubs, to be set up by states in partnership with private sector.

Budget 2026's biopharma push comes amid a sharp rise in chronic disease

Union Budget 2026–27 allocates ₹10,000 crore for India’s biopharma ambitions

by Neetu Chandra Sharma |Feb 1, 2026

Budget 2026: According to government and ICMR estimates, non-communicable diseases now account for over 55% of India’s total disease burden.